2026 Healthy Value Enhanced Comprehensive Formulary (Medicare Part D drug list)
This document is the 2026 formulary (drug list) for Medicare Plus Blue Group PPO and Prescription Blue Group PDP and governs which prescription drugs and biologicals are covered, along with coverage rules (prior authorization, step therapy, quantity limits) and member processes for exceptions and transitions.
No material clinical or coverage changes in this revision.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.